MEthotrexate Response in Treatment of UC - MERIT-UC

甲氨蝶呤治疗 UC 的反应 - MERIT-UC

• 批准号: 8703089
• 负责人: Hans H. Herfarth
• 金额: $ 154.89万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-15 至 2016-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8703089
• 关键词: 6-Mercaptopurine; Americas; Anti-Tumor Necrosis Factor Therapy; Azathioprine; Biological Availability; Case Series; Clinical; Clinical Research; Conflict (Psychology); Crohn' s disease; DNA; Data; Disease remission; Dose; Enrollment; Foundations; Grant; Institutional Review Boards; Investigational New Drug Application; Lead; Libraries; Literature; Maintenance Therapy; Marketing; Methotrexate; Modeling; Oral Administration; Patients; Pharmaceutical Preparations; Pharmacogenomics; Placebo Control; Placebos; Plasma; Principal Investigator; Protocols documentation; Publishing; Relapse; Research; Research Infrastructure; Rheumatoid Arthritis; Route; Safety; Site; Steroids; Therapeutic; Time; Ulcerative Colitis; clinical efficacy; effective therapy; experience; infliximab; large bowel Crohn' s disease; novel; placebo controlled study; prospective; research clinical testing; response; thiopurine

DESCRIPTION (provided by applicant): We propose a prospective placebo controlled study to investigate the safety and efficacy of 25 mg MIX applied subcutaneously once weekly in patients with active UC, who are either steroid dependent or are intolerant or not responding to azathioprine/6-mercaptopurine therapy or have no response/ lost response to infliximab prior to the study inclusion. In the setting of an implementation-planning (U34) grant we finalized the study protocol and associated formal requirements for this trial. We obtained a lead IRB approval and are currently obtaining IRB approvals of the participating sites. We registered an IND number (108,560) with the FDA and established the study infrastructure for this prospective placebo-controlled multi-center study using the center framework of the Crohn's and Colitis Foundation of America (CCFA) Clinical Research Alliance (CRA). The Specific Aims of the trial are: 1) To evaluate the safety and tolerability of 25 mg MTX applied sq once weekly over a time period of 48 weeks. 2) To evaluate the relapse-free survival of MTX maintenance therapy compared to placebo over a time period of 32 weeks. 3) To evaluate the efficacy of MTX over a time period of 16 weeks to induce steroid free remission. 4) To establish a DNA, plasma and serum library to enable the evaluation of clinical and pharmacogenomic models to predict the response to MTX therapy in patients with UC.

描述（由申请方提供）：我们提出了一项前瞻性安慰剂对照研究，旨在研究25 mg MIX每周一次皮下给药在活动性UC患者中的安全性和疗效，这些患者在研究入选前要么是类固醇依赖性患者，要么是对硫唑嘌呤/6-巯基嘌呤治疗不耐受或无反应的患者，要么是对英夫利西单抗无反应/无反应的患者。在实施计划（U34）资助的背景下，我们最终确定了本试验的研究方案和相关正式要求。我们获得了IRB的主要批准，目前正在获得参与研究中心的IRB批准。我们在FDA注册了IND编号（108，560），并使用美国克罗恩病和结肠炎基金会（CCFA）临床研究联盟（CRA）的中心框架为这项前瞻性安慰剂对照多中心研究建立了研究基础设施。本试验的具体目的是：1）评价25 mg MTX每周一次（每次2次）给药48周的安全性和耐受性。2)评估MTX维持治疗与安慰剂相比32周内的无复发生存率。3)评价MTX在16周时间内诱导无类固醇缓解的疗效。4)建立DNA、血浆和血清文库，以评估临床和药物基因组学模型，预测UC患者对MTX治疗的反应。